Julie Rubinstein sold $920k of ADPT
President and COO at Adaptive Biotechnologies Corp. 35,643 shares at an average of $25.81, traded Oct 9, 2026, filed Oct 13, 2026.
Score components
This filing reached EDGAR on Oct 13, 2026, so its score and components open to free visitors on Oct 20, 2026. The trade itself, the rows in the filing and the price context are public now.
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001780664-26-000039, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 9, 2026 | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 5 h ago |
| Oct 9, 2026 | SOpen-market sale Common Stock10b5-1 | -11,881 | $26.41 | $314k | 377,802 | 5 h ago |
| Oct 12, 2026 | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 5 h ago |
| Oct 12, 2026 | SOpen-market sale Common Stock10b5-1 | -9,181 | $25.35 | $233k | 380,502 | 5 h ago |
| Oct 12, 2026 | SOpen-market sale Common Stock10b5-1 | -2,700 | $26.07 | $70k | 377,802 | 5 h ago |
| Oct 13, 2026 | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 5 h ago |
| Oct 13, 2026 | SOpen-market sale Common Stock10b5-1 | -11,881 | $25.50 | $303k | 377,802 | 5 h ago |
| Oct 9, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 296,610 | 5 h ago |
| Oct 12, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 284,729 | 5 h ago |
| Oct 13, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 272,848 | 5 h ago |
Related signals
Other insiders at Adaptive Biotechnologies Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $948k 35,643 shares | -9% | |
| Pro nowfree Oct 15, 2026 | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $193k 6,444 shares | -2% | |
| 22Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $758k 26,792 shares | -11% | |
| 25Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $1.0M 35,643 shares | -9% | |
| 23Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $3.2M 115,406 shares | -34% | |
| 8Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $32k 1,195 shares | -0% | |
| 48Moderate | Adaptive Biotechnologies Corp | Katey Einterz Owen director | $250k 9,615 shares | -11% | |
| 46Moderate | Adaptive Biotechnologies Corp | Robert Hershberg director | $748k 30,664 shares | -40% | |
| 50Moderate | Adaptive Biotechnologies Corp | Peter M Neupert director | $3.1M 124,690 shares | -49% | |
| 55Moderate | Adaptive Biotechnologies Corp | Chad M Robins CEO and Chairman | $15M 600,000 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.